Respiratory medicine最新文献

{"title":"Longitudinal respiratory trajectories in motor neuron disease phenotypes: Multiparametric characterization and clinical management","authors":"Pilar M. Ferraro ,&nbsp;Elena Mollar ,&nbsp;Laura Melissari ,&nbsp;Martina Buscema ,&nbsp;Emiliano Bagnoli ,&nbsp;Corrado Cabona ,&nbsp;Chiara Gemelli ,&nbsp;Manuela Vignolo ,&nbsp;Cinzia Maranzana ,&nbsp;Maura Marogna ,&nbsp;Lorenzo Ferrera ,&nbsp;Alessandro Beronio ,&nbsp;Claudio De Michelis ,&nbsp;Valeria Bergamaschi ,&nbsp;Margherita Monti Bragadin ,&nbsp;Giampaolo Brichetto ,&nbsp;Fulvio Braido ,&nbsp;Fabrizio Rao","doi":"10.1016/j.rmed.2025.108003","DOIUrl":"10.1016/j.rmed.2025.108003","url":null,"abstract":"<div><h3>Background</h3><div>Motor neuron diseases (MNDs) encompass amyotrophic lateral sclerosis (ALS), pure/predominant upper (pUMN) and lower motor neuron (pLMN) phenotypes. However respiratory studies have mainly focused on bulbar (B-ALS) and spinal (S-ALS) onset ALS, while little is known in other MNDs. In this study we therefore aimed at characterizing baseline and longitudinal patterns of respiratory involvement and their clinical management in MND patients stratified by their clinical phenotype.</div></div><div><h3>Methods</h3><div>Serial pulmonary function tests (PFTs) (spirometry, arterial blood gas analysis, overnight pulse oximetry and peak cough expiratory flow) records of the MND patients hospitalized between 2020 and 2024 were reviewed. Using longitudinal examinations, deltas of variation in respiratory measures were generated and frequency and timings of non-invasive ventilation (NIV) adaptation were evaluated. Data were compared between phenotypes using the Kruskal–Wallis test with Bonferroni adjustment.</div></div><div><h3>Results</h3><div>42 S-ALS, 105 B-ALS, 42 pLMN and 31 pUMN patients were included. Both at baseline and longitudinally, B-ALS showed the worst respiratory parameters, followed by pLMN, S-ALS and pUMN. NIV adaptation was equally frequent between groups, but earlier in B-ALS compared to pUMN (p = 0.01). At baseline, B-ALS showed worse spirometry and PCEF only, but compared to all the other phenotypes (p from &lt;0.0001 to 0.03). Longitudinally, they conversely exhibited more severe decline in all PFTs, but only relative to pUMN (p from 0.0009 to 0.04), with deltas of variation comparable to the ones observed in S-ALS and pLMN. Among NIV users, more severe PCEF and spirometry impairment further emerged in S-ALS compared to pUMN (p from 0.01 to 0.04).</div></div><div><h3>Conclusions</h3><div>We evidenced convergent trajectories of respiratory decline across B-ALS, S-ALS and pLMN, highlighting the utility of multimodal assessments for tracking progressing respiratory disturbances. These findings have potential to accelerate earlier and more tailored respiratory management across diverse MND phenotypes.</div></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"239 ","pages":"Article 108003"},"PeriodicalIF":3.5,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143436842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimising outcomes for adults with cystic fibrosis taking CFTR modulators by individualising care: Personalised data linkage to understand treatment optimisation (PLUTO), a novel clinical framework","authors":"Robert D. Sandler ,&nbsp;Alan Anderson ,&nbsp;Tracy Barnett ,&nbsp;Stephen J. Bourke ,&nbsp;Sarah Cameron ,&nbsp;Stephen J. Chapman ,&nbsp;Jocelyn Choyce ,&nbsp;Thom Daniels ,&nbsp;Tracey Daniels ,&nbsp;Sophie Dawson ,&nbsp;Simon Doe ,&nbsp;Michael Dooney ,&nbsp;Carlos Echevarria ,&nbsp;Penny Galey ,&nbsp;Giles Fitch ,&nbsp;Lana Y.H. Lai ,&nbsp;Julia A. Nightingale ,&nbsp;Michelle Thomas ,&nbsp;Rachael Thompson ,&nbsp;Joanna Whitehouse ,&nbsp;Martin J. Wildman","doi":"10.1016/j.rmed.2025.107995","DOIUrl":"10.1016/j.rmed.2025.107995","url":null,"abstract":"","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"239 ","pages":"Article 107995"},"PeriodicalIF":3.5,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143436462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of traditional Chinese exercise on pulmonary function in middle-aged and older patients with stable chronic obstructive pulmonary disease: A randomized controlled trial","authors":"Ziying Chen ,&nbsp;Hongyu Yue ,&nbsp;Yuanjia Gu ,&nbsp;Chaoqun Xie ,&nbsp;Jianwen Ma ,&nbsp;Fangfang Xie ,&nbsp;Guangdong Wang ,&nbsp;Fei Yao","doi":"10.1016/j.rmed.2025.107997","DOIUrl":"10.1016/j.rmed.2025.107997","url":null,"abstract":"<div><h3>Background</h3><div>Traditional Chinese exercise (TCE) has been shown effective for chronic obstructive pulmonary disease (COPD). However, there are no studies investigating the effect of traditional Chinese exercise (TCE) programme on COPD. The aim of this study was to evaluate the effectiveness of specific TCE programme on the pulmonary function in patients with COPD.</div></div><div><h3>Methods</h3><div>76 patients with COPD was randomly assigned to receive either TCE group or control group in a 1:1 ratio. The primary outcome was changes in forced vital capacity (FVC) from baseline to 12 weeks. Secondary outcomes included forced expiratory volume in the first second (FEV1), tidal volume (VT), inspiratory capacity (IC), expiratory reserve volume (ERV), FEV1/FVC, peak expiratory flow (PEF), the 6-min walking test (6MWT), the COPD Assessment Test (CAT), the Short Form 36-item Health Survey (SF-36), modified medical research council scale (mMRC).</div></div><div><h3>Results</h3><div>After 12 weeks, the TCE group demonstrated a significantly greater improvement of FVC (−12.67; 95 % CI, −18.21 to −7.15; <em>P</em> &lt; 0.001) and FEV1 (−9.70; 95 % CI, −13.73 to −5.68; <em>P</em> &lt; 0.001). But there was no statistically significant difference between groups in FEV1/FVC, PEF, VT, IC or ERV. Besides, patients in the TCE group also reported a statistically significant within-group difference at week 12 in CAT, mMRC and 6MWT. As for eight dimensions of SF-36, patients in TCE group had higher scores in SF-36 (<em>P</em> &lt; 0.05 for 8 dimensions).</div></div><div><h3>Conclusion</h3><div>Our results demonstrate that the traditional Chinese exercise can serve as an effective therapeutic tool for middle-aged and older patients with COPD.</div></div><div><h3>Trial registration number</h3><div>Chinese Clinical Trial Registry, ChiCTR2300069283, <span><span>https://www.chictr.org.cn/showproj.html?proj=192116</span><svg><path></path></svg></span>.</div></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"239 ","pages":"Article 107997"},"PeriodicalIF":3.5,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143430214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Geographic variability of interstitial lung disease diagnoses and impact of air pollution on disease outcomes","authors":"Annalise Bagust ,&nbsp;Cheng Zhao ,&nbsp;Lauren Troy ,&nbsp;Joe Van Buskirk ,&nbsp;Astrid Gardiner ,&nbsp;Megan Harrison ,&nbsp;Nathan Mortimer ,&nbsp;Luke D. Knibbs ,&nbsp;Tamera J. Corte","doi":"10.1016/j.rmed.2025.107996","DOIUrl":"10.1016/j.rmed.2025.107996","url":null,"abstract":"<div><h3>Background and objective</h3><div>Anecdotal reports suggest interstitial lung disease (ILD) phenotypes vary regionally. We aimed to assess geographic variability of ILD diagnoses and impact of air quality on disease outcomes across the state of New South Wales, Australia.</div></div><div><h3>Methods</h3><div>Consecutive patients referred to an ILD multidisciplinary meeting, receiving referrals from across NSW (Feb 2014–Feb 2017), were included. Comparative frequencies of ILD diagnoses between regions were compared using Fisher's exact tests. Satellite-based land use regression models were used to estimate mean annual air pollution exposure for patients' home address at diagnosis. Associations between air pollution exposure and mortality and disease progression were assessed using multivariable Cox proportional hazard models.</div></div><div><h3>Results</h3><div>437 ILD patients [mean age 67 ± 13 years; 41 % female, 48 % ever-smokers] were included. Air pollution at the year of diagnosis was 6.6 ± 2.0 μg/m³ for PM2.5, and 8.1 ± 4.2 ppb for NO₂. Exposure to NO₂ was significantly higher in major cities than in regional areas (p &lt; 0.001), while exposure to PM2.5 did not differ significantly (p = 0.373). In regional and remote areas, relative frequency of hypersensitivity pneumonitis (HP) was 1.75 times higher (p = 0.078) than in major cities. Among 329 ILD patients with ≥6 months follow-up data, disease outcomes were associated with specific ILD diagnosis and baseline FVC, but not associated with air pollution exposure.</div></div><div><h3>Conclusion</h3><div>We found a trend towards higher relative frequency of HP and lower relative frequency of non-IPF IIP in regional and remote areas compared to major cities. There was no association between mean air pollution exposure at diagnosis and disease outcomes.</div></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"239 ","pages":"Article 107996"},"PeriodicalIF":3.5,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143426079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac-lung ultrasound and ventilator-weaning: Navigating the nuances","authors":"Rohan Magoon","doi":"10.1016/j.rmed.2025.107992","DOIUrl":"10.1016/j.rmed.2025.107992","url":null,"abstract":"","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"239 ","pages":"Article 107992"},"PeriodicalIF":3.5,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143426078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MHR as a promising predictor for coronary artery disease in COPD patients: Insights from a retrospective nomogram study","authors":"Feng Sun ,&nbsp;Mei Ye ,&nbsp;Ayididar Jumahan ,&nbsp;Aidibai Aainiwaier ,&nbsp;Yu Xia","doi":"10.1016/j.rmed.2025.107993","DOIUrl":"10.1016/j.rmed.2025.107993","url":null,"abstract":"<div><h3>Background and objective</h3><div>Chronic obstructive pulmonary disease (COPD) frequently co-occurs with coronary artery disease (CAD), adversely affecting patients morbidity and mortality. Identifying new risk factors for CAD in COPD patients is essential for improving clinical management and patients outcomes.</div></div><div><h3>Methods</h3><div>This retrospective case-control study analyzed 406 COPD patients who underwent coronary artery computed tomography angiography (CCTA). Patients were categorized into co-CAD and non-CAD groups based on CCTA findings. Demographic and laboratory data were assessed to determine independent risk factors for CAD in COPD patients using univariate and multivariate logistic regression analyses.</div></div><div><h3>Results</h3><div>The co-CAD group was significantly older, had a higher prevalence of males, and included a higher proportion of individuals with hypertension, diabetes, cardiovascular diseases, as well as cerebrovascular diseases, exhibiting lower FEV1 values (P &lt; 0.05). This group also exhibited higher levels of HbA1c, IL-6, monocyte count, and MHR (P &lt; 0.05). Multivariate logistic regression identified age, hypertension, and MHR as independent predictors of CAD. A nomogram incorporating these predictors demonstrated robust predictive accuracy with an area under the ROC curve of 0.758 (95 % CI: 0.704–0.814), effectively stratifying patients into high and low risk for CAD.</div></div><div><h3>Conclusion</h3><div>The identification of MHR as an independent predictor of CAD in COPD patients opens new avenues for understanding cardiovascular comorbidities. The nomogram's integration of MHR with age and hypertension provides an effective tool for early CAD detection and management, promising to enhance clinical outcomes and decrease mortality rates in COPD patients. These insights may inform future preventative strategies against CAD in COPD.</div></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"239 ","pages":"Article 107993"},"PeriodicalIF":3.5,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing adsorptive blood purification modalities for sepsis patients: A systematic review and network meta-analysis","authors":"Huameng Xing ,&nbsp;Yuxuan Wei ,&nbsp;Dongmei Zhang ,&nbsp;Zheng Jiang ,&nbsp;Jianhua Qin ,&nbsp;Santao Ou ,&nbsp;Weihua Wu","doi":"10.1016/j.rmed.2025.107994","DOIUrl":"10.1016/j.rmed.2025.107994","url":null,"abstract":"<div><h3>Purpose</h3><div>Hemoadsorption is a promising therapeutic modality for sepsis, however, the most effective approach is unknown. This meta-analysis aimed to compare the efficacy of different adsorptive blood purification (ABP) modalities in patients with sepsis.</div></div><div><h3>Materials and methods</h3><div>Randomized controlled trials (RCTs) investigating the clinical efficacy of ABP modalities in patients with sepsis were retrieved from English databases from inception up to October 14, 2024. The data were analyzed using Stata15 and R software. Quality assessment and publication bias were assessed using the Cochrane Risk of Bias Assessment Tool and funnel plots, respectively. The outcomes of the meta-analysis were hospital mortality, oxygenation index, ICU stay days, and blood lactate concentration.</div></div><div><h3>Results</h3><div>A total of 47 RCTs were identified, comprising 9 ABP modalities. In terms of cumulative ranking probability, the HA330 modality achieved the highest reduction in hospital mortality (99.5 %) and ICU stay days (97.2 %), whereas CPFA showed the highest reduction in oxygenation index (94.9 %) and oXiris had the highest reduction in lactate (95.7 %).</div></div><div><h3>Conclusions</h3><div>HA330 and PMX showed superior overall efficacy in sepsis patients compared with other modalities, although there was potential heterogeneity. However, further RCTs with large samples are advocated to test new approaches of hemosorption and validate the present findings.</div></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"239 ","pages":"Article 107994"},"PeriodicalIF":3.5,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143418943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A patient journey map for people living with autoimmune pulmonary alveolar proteinosis","authors":"Ali Ataya ,&nbsp;Niki Plomaritis ,&nbsp;Michele Rhee ,&nbsp;Swaminathan Perinkulam Sathyanarayanan ,&nbsp;Brian Robinson","doi":"10.1016/j.rmed.2025.107990","DOIUrl":"10.1016/j.rmed.2025.107990","url":null,"abstract":"<div><h3>Introduction</h3><div>Patients with autoimmune pulmonary alveolar proteinosis (PAP) face a complicated journey (physically, emotionally, and financially) to receive the correct diagnosis and treatment. We developed a patient journey map (PJM) to describe the experiences and needs of patients with autoimmune PAP in the USA.</div></div><div><h3>Methods</h3><div>This PJM was developed in four stages: (1) analysis of existing literature; (2) patient advisory board meetings (n = 7); (3) an online survey (n = 19); and (4) a validation workshop (n = 6).</div></div><div><h3>Results</h3><div>Four phases of the patient journey were identified: (1) symptoms and experience before diagnosis; (2) diagnosis; (3) treatment; and (4) ongoing monitoring. Patients reported heterogeneous and indirect diagnostic pathways, often waiting months or years for the correct diagnosis. The majority reported at least one misdiagnosis, most commonly pneumonia. Treatment pathways varied substantially, and current treatments and off-label therapies were frequently described as burdensome, emotionally taxing, and/or financially worrisome. Patients described their journey as an “<em>emotional rollercoaster</em>,” especially during pre-diagnosis and treatment. Patients reported common barriers to care, particularly insurance problems and access to expert care. Patients specifically cited the need for improved education on autoimmune PAP within the medical community and increased help with insurance challenges related to current treatments.</div></div><div><h3>Conclusions</h3><div>This PJM provides insights on patients’ journeys with autoimmune PAP. Patients reported inconsistent, burdensome, and circuitous journeys. This PJM provides the medical community with valuable information on patients’ needs and increases awareness of this rare disease. Over time, these factors may improve diagnosis, treatment, and the holistic experience of patients with autoimmune PAP.</div></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"240 ","pages":"Article 107990"},"PeriodicalIF":3.5,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes in lung transplant recipients on azathioprine compared to mycophenolate","authors":"David M. Sanborn ,&nbsp;Joelle N. Friesen ,&nbsp;Hemang Yadav ,&nbsp;Cassie C. Kennedy ,&nbsp;Mark E. Wylam ,&nbsp;Steve G. Peters ,&nbsp;John P. Scott ,&nbsp;Sahar A. Saddoughi ,&nbsp;Kelly M. Pennington","doi":"10.1016/j.rmed.2025.107991","DOIUrl":"10.1016/j.rmed.2025.107991","url":null,"abstract":"<div><h3>Intro</h3><div>A three-drug immunosuppression regimen to prevent graft loss is the cornerstone of therapy following lung transplantation. Direct comparisons between maintenance regimens including mycophenolate (MMF) and azathioprine (AZA) are limited in the lung transplant population.</div></div><div><h3>Methods</h3><div>We completed a retrospective cohort study of adult (≥18 years of age) lung transplant recipients at Mayo Clinic (Rochester, MN) from January 1, 2009 through July 1, 2022 and compared outcomes in patients on AZA vs MMF. Our primary outcome was clinically significant acute cellular rejection. Secondary outcomes included graft loss, drug interruption, chronic lung allograft dysfunction (CLAD), and infection. Analyses were performed with Multivariable Cox Regression with transplant era and induction immunosuppression agent as covariables.</div></div><div><h3>Results</h3><div>224 patients were included, 88 on AZA and 136 on MMF. The risk of clinically significant rejection was greater in the AZA group compared to the MMF group (HR, 1.76; 95 % CI 1.12–2.79; <em>P</em> = 0.02). Medication interruption was also higher in the AZA (HR, 1.47; 95 % CI 1.04–2.08; <em>P</em> = 0.026). Rates of CLAD, graft loss, and infection were similar between the groups.</div></div><div><h3>Conclusion</h3><div>In this cohort, MMF was associated with lower risk of clinically significant acute cellular rejection and drug interruption when compared to AZA. Similar rates of CLAD, graft loss, and infection were observed.</div></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"239 ","pages":"Article 107991"},"PeriodicalIF":3.5,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143410330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of GLI-2021 standards with ECSC standards for static lung volume interpretation in patients with respiratory diseases","authors":"Pierre-Marie Wardyn ,&nbsp;Virginie de Broucker ,&nbsp;Thierry Perez ,&nbsp;Silvia Demoulin-Alexikova ,&nbsp;Jean-Louis Edme ,&nbsp;Sébastien Hulo","doi":"10.1016/j.rmed.2025.107988","DOIUrl":"10.1016/j.rmed.2025.107988","url":null,"abstract":"<div><h3>Background</h3><div>In 2021, the Global Lung Function Initiative (GLI) has published new reference equations for static lung volumes (GLI-2021). Many learned societies recommend the use of GLI reference values for interpreting pulmonary function tests (PFT), while pointing out the need for clinicians to be aware of the consequences for their routine practice. We aimed to compare the GLI-2021 reference values and the 1993 European Coal and Steel Community (ECSC) standards on the interpretation of static lung volume data in patients with a probable static hyperinflation or a probable restrictive ventilatory disorder.</div></div><div><h3>Methods</h3><div>We analyzed plethysmographic PFT data from 2 groups of patients: a group of patients with symptoms compatible with chronic bronchitis (CB) and a group of patients with symptoms compatible with interstitial lung disease (ILD). We investigated discrepancies in the evaluations of static lung volumes when using the ECSC vs. the GLI-2021 reference values.</div></div><div><h3>Results</h3><div>2897 sets of PFT results (including 1598 in men) were included. In the CB group, the proportion of hyperinflation was higher for both sexes with the GLI-2021 standards. In the ILD group, the proportion of restrictive ventilatory disorders was higher in women but lower in men with the GLI-2021 standards.</div></div><div><h3>Conclusion</h3><div>A move from use of the ECSC standards for static lung volumes to the GLI-2021 standards might lead to a higher estimated proportion of hyperinflation (particularly in participants with CB), together with changes in the proportion of restrictive ventilatory disorders (a lower value in men and a higher value in women with ILD).</div></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"239 ","pages":"Article 107988"},"PeriodicalIF":3.5,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143391644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}